S&P 500   4,690.65 (+2.16%)
DOW   35,755.95 (+1.50%)
QQQ   397.89 (+3.03%)
AAPL   170.63 (+3.21%)
MSFT   334.87 (+2.66%)
FB   323.97 (+1.92%)
GOOGL   2,938.45 (+2.63%)
AMZN   3,543.19 (+3.38%)
TSLA   1,045.74 (+3.64%)
NVDA   321.17 (+6.92%)
BABA   125.11 (+1.22%)
NIO   33.27 (+2.88%)
CGC   10.86 (+7.00%)
AMD   145.21 (+4.42%)
GE   98.11 (+2.19%)
MU   86.56 (+4.98%)
T   23.15 (-0.56%)
F   19.92 (+3.64%)
DIS   150.38 (+0.01%)
PFE   51.37 (-0.21%)
AMC   31.27 (+8.61%)
ACB   6.45 (+8.04%)
BA   211.07 (+2.52%)
S&P 500   4,690.65 (+2.16%)
DOW   35,755.95 (+1.50%)
QQQ   397.89 (+3.03%)
AAPL   170.63 (+3.21%)
MSFT   334.87 (+2.66%)
FB   323.97 (+1.92%)
GOOGL   2,938.45 (+2.63%)
AMZN   3,543.19 (+3.38%)
TSLA   1,045.74 (+3.64%)
NVDA   321.17 (+6.92%)
BABA   125.11 (+1.22%)
NIO   33.27 (+2.88%)
CGC   10.86 (+7.00%)
AMD   145.21 (+4.42%)
GE   98.11 (+2.19%)
MU   86.56 (+4.98%)
T   23.15 (-0.56%)
F   19.92 (+3.64%)
DIS   150.38 (+0.01%)
PFE   51.37 (-0.21%)
AMC   31.27 (+8.61%)
ACB   6.45 (+8.04%)
BA   211.07 (+2.52%)
S&P 500   4,690.65 (+2.16%)
DOW   35,755.95 (+1.50%)
QQQ   397.89 (+3.03%)
AAPL   170.63 (+3.21%)
MSFT   334.87 (+2.66%)
FB   323.97 (+1.92%)
GOOGL   2,938.45 (+2.63%)
AMZN   3,543.19 (+3.38%)
TSLA   1,045.74 (+3.64%)
NVDA   321.17 (+6.92%)
BABA   125.11 (+1.22%)
NIO   33.27 (+2.88%)
CGC   10.86 (+7.00%)
AMD   145.21 (+4.42%)
GE   98.11 (+2.19%)
MU   86.56 (+4.98%)
T   23.15 (-0.56%)
F   19.92 (+3.64%)
DIS   150.38 (+0.01%)
PFE   51.37 (-0.21%)
AMC   31.27 (+8.61%)
ACB   6.45 (+8.04%)
BA   211.07 (+2.52%)
S&P 500   4,690.65 (+2.16%)
DOW   35,755.95 (+1.50%)
QQQ   397.89 (+3.03%)
AAPL   170.63 (+3.21%)
MSFT   334.87 (+2.66%)
FB   323.97 (+1.92%)
GOOGL   2,938.45 (+2.63%)
AMZN   3,543.19 (+3.38%)
TSLA   1,045.74 (+3.64%)
NVDA   321.17 (+6.92%)
BABA   125.11 (+1.22%)
NIO   33.27 (+2.88%)
CGC   10.86 (+7.00%)
AMD   145.21 (+4.42%)
GE   98.11 (+2.19%)
MU   86.56 (+4.98%)
T   23.15 (-0.56%)
F   19.92 (+3.64%)
DIS   150.38 (+0.01%)
PFE   51.37 (-0.21%)
AMC   31.27 (+8.61%)
ACB   6.45 (+8.04%)
BA   211.07 (+2.52%)
NASDAQ:CMMB

Chemomab Therapeutics Stock Forecast, Price & News

$8.31
+0.88 (+11.84%)
(As of 12/7/2021 01:05 PM ET)
Add
Compare
Today's Range
$7.88
$8.37
50-Day Range
$7.43
$11.95
52-Week Range
$6.89
$168.80
Volume
629 shs
Average Volume
228,864 shs
Market Capitalization
$94.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.89
30 days | 90 days | 365 days | Advanced Chart
Receive CMMB News and Ratings via Email

Sign-up to receive the latest news and ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About Chemomab Therapeutics

Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 16, 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Headlines

Aegis Begins Coverage on Chemomab Therapeutics (NASDAQ:CMMB)
December 7, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CMMB
Fax
N/A
Employees
2,020
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$5.75 per share

Profitability

Net Income
$-11.61 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
9,912,000
Market Cap
$94.72 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/11/2021
Today
12/07/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/08/2022

MarketRank

Overall MarketRank

1.80 out of 5 stars

Medical Sector

900th out of 1,394 stocks

Pharmaceutical Preparations Industry

426th out of 673 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












Chemomab Therapeutics (NASDAQ:CMMB) Frequently Asked Questions

Is Chemomab Therapeutics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chemomab Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Chemomab Therapeutics stock.
View analyst ratings for Chemomab Therapeutics
or view top-rated stocks.

Are investors shorting Chemomab Therapeutics?

Chemomab Therapeutics saw a drop in short interest in November. As of November 15th, there was short interest totaling 49,700 shares, a drop of 21.2% from the October 31st total of 63,100 shares. Based on an average daily trading volume, of 150,900 shares, the short-interest ratio is presently 0.3 days. Approximately 0.6% of the company's shares are short sold.
View Chemomab Therapeutics' Short Interest
.

When is Chemomab Therapeutics' next earnings date?

Chemomab Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for Chemomab Therapeutics
.

How were Chemomab Therapeutics' earnings last quarter?

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) released its earnings results on Thursday, November, 11th. The company reported ($0.26) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.02) by $0.24.
View Chemomab Therapeutics' earnings history
.

What price target have analysts set for CMMB?

3 equities research analysts have issued 12-month price targets for Chemomab Therapeutics' stock. Their forecasts range from $30.00 to $45.00. On average, they expect Chemomab Therapeutics' share price to reach $39.00 in the next twelve months. This suggests a possible upside of 369.3% from the stock's current price.
View analysts' price targets for Chemomab Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Chemomab Therapeutics' key executives?

Chemomab Therapeutics' management team includes the following people:
  • Dr. Adi Mor George Ph.D., Co-Founder, CEO, Chief Scientific Officer & Exec. Director (Age 39)
  • Ms. Sigal Fattal, Interim Chief Financial Officer (Age 50)
  • Dr. Arnon Aharon, Chief Medical Officer (Age 52)

What is Chemomab Therapeutics' stock symbol?

Chemomab Therapeutics trades on the NASDAQ under the ticker symbol "CMMB."

Who are Chemomab Therapeutics' major shareholders?

Chemomab Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Advisor Group Holdings Inc. (0.48%), Meitav Dash Investments Ltd. (0.33%), Geode Capital Management LLC (0.12%) and Yahav Achim Ve Achayot Provident Funds Management Co Ltd. (0.03%).

Which institutional investors are selling Chemomab Therapeutics stock?

CMMB stock was sold by a variety of institutional investors in the last quarter, including Meitav Dash Investments Ltd..

Which institutional investors are buying Chemomab Therapeutics stock?

CMMB stock was bought by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc., Geode Capital Management LLC, and Yahav Achim Ve Achayot Provident Funds Management Co Ltd..

How do I buy shares of Chemomab Therapeutics?

Shares of CMMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chemomab Therapeutics' stock price today?

One share of CMMB stock can currently be purchased for approximately $8.31.

How much money does Chemomab Therapeutics make?

Chemomab Therapeutics has a market capitalization of $94.72 million. The company earns $-11.61 million in net income (profit) each year or ($4.74) on an earnings per share basis.

How many employees does Chemomab Therapeutics have?

Chemomab Therapeutics employs 2,020 workers across the globe.

What is Chemomab Therapeutics' official website?

The official website for Chemomab Therapeutics is www.chemomab.com.

Where are Chemomab Therapeutics' headquarters?

Chemomab Therapeutics is headquartered at KIRYAT ATIDIM BUILDING 7, TEL AVIV L3, 6158002.

How can I contact Chemomab Therapeutics?

Chemomab Therapeutics' mailing address is KIRYAT ATIDIM BUILDING 7, TEL AVIV L3, 6158002. The company can be reached via phone at 972-77-331-0156 or via email at [email protected].


This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.